SMTL ID : 6ps5.1

XFEL beta2 AR structure by ligand exchange from Timolol to Propranolol.

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.90 Å

Oligo State

monomer

Ligands

1 x SNP: 1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL(Non-covalent)

SNP.1: 15 residues within 4Å: Chain A: W.133, T.134, D.137, V.138, V.141, F.217, S.227, S.228, S.231, W.438, F.441, F.442, N.445, N.464, Y.468 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:W.133, A:T.134, A:V.138, A:V.141, A:F.217 Hydrogen bonds: A:D.137, A:N.464, A:Y.468 pi-Stacking: A:F.442

4 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 7 residues within 4Å: Chain A: T.90, V.91, T.92, R.155, Y.165, Q.166, S.167 6 PLIP interactions: 6 interactions with chain A Hydrogen bonds: A:T.90, A:V.91, A:T.92, A:Y.165, A:S.167 Salt bridges: A:R.155 SO4.3: 3 residues within 4Å: Chain A: K.422, K.425, R.480 3 PLIP interactions: 3 interactions with chain A Salt bridges: A:K.422, A:K.425, A:R.480 SO4.4: 5 residues within 4Å: Chain A: F.367, T.368, N.369, S.370, N.385 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:F.367, A:N.369, A:N.369, A:S.370, A:N.385 SO4.5: 4 residues within 4Å: Chain A: T.395, P.396, N.397, R.398 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:N.397, A:N.397, A:R.398

1 x CLR: CHOLESTEROL(Non-covalent)

CLR.6: 10 residues within 4Å: Chain A: Y.94, T.97, S.98, C.101, V.105, R.175, I.178, L.179, W.182 Ligands: OLC.10 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:Y.94, A:T.97, A:V.105, A:R.175, A:I.178, A:L.179, A:W.182 Hydrogen bonds: A:R.175

2 x OLA: OLEIC ACID(Non-covalent)(Non-functional Binders)

OLA.7: 7 residues within 4Å: Chain A: M.60, M.64, E.458, I.461, W.465, I.466, V.469 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:W.465, A:W.465, A:I.466 OLA.8: 1 residues within 4Å: Ligands: OLC.9 No protein-ligand interaction detected (PLIP)

4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)

OLC.9: 6 residues within 4Å: Chain A: F.73, V.76, T.80, L.491, L.492 Ligands: OLA.8 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:F.73, A:F.73, A:F.73, A:V.76, A:L.492 OLC.10: 3 residues within 4Å: Chain A: I.79, C.101 Ligands: CLR.6 No protein-ligand interaction detected (PLIP) OLC.11: 6 residues within 4Å: Chain A: V.150, V.153, D.154, F.157, L.168, L.169 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:V.150 OLC.12: 3 residues within 4Å: Chain A: F.113, F.125, W.129 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:W.129

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ishchenko, A. et al., Toward G protein-coupled receptor structure-based drug design using X-ray lasers. Iucrj (2019)

Release Date

2019-11-13

Peptides

Fusion protein of Beta-2 adrenergic receptor and T4 Lysozyme: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Membrane

We predict this structure to be a membrane protein.
Show / Hide

Fusion protein of Beta-2 adrenergic receptor and T4 Lysozyme

Related Entries With Identical Sequence